20
Participants
Start Date
June 30, 2005
Primary Completion Date
July 31, 2008
Study Completion Date
April 30, 2009
Deferoxamine
Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
Deferiprone (L1)
The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
Weill Medical College of Cornell University, New York
Children's Hospital of Los Angeles, Los Angeles
Children's Hospital, Oakland
Children's Memorial Hospital, Chicago
Children's Hospital, Boston
Children's Hospital of Philadelphia, Philadelphia
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Carelon Research
OTHER